Have a personal or library account? Click to login
Stability and bifurcation analysis of a nested multi-scale model for COVID-19 viral infection Cover

Stability and bifurcation analysis of a nested multi-scale model for COVID-19 viral infection

Open Access
|Jun 2024

Full Article

1
Introduction

Infectious diseases with their host-parasite interactions represent a complex system involving components and processes that operate at different levels of time, space, and biological organization [19]. Infectious disease dynamics involve thousands of molecules, complicated interactions of the pathogen with the host and also with the environment. Therefore, to understand disease dynamics in-depth, one must understand the processes at these different levels of manifestation of infectious diseases, and the interactions between these levels. The two most studied scales in the transmission of infectious disease systems are the within-host and between-host scales. Although these models have provided useful information about virus-cell interactions at the level of a single host and disease transmission between hosts, disease modelers see the need to integrate or link these models to obtain a better understanding of the dynamics of infectious disease spread.

Several studies on infectious diseases have shown that disease transmission depends on within-host processes [2,14,21,23,24,31,37]. In particular, these studies have shown that the transmission potential of an infected host depends on the pathogen load and increases with increasing pathogen load. The different functional relationships between host infectivity and pathogen load have been identified. Studies of dengue and human immunodeficiency virus (HIV) transmission revealed a sigmoidal functional relationship between host infectivity and the pathogen load at the within-host level [31,37]. Studies that discuss similar functional relationships between host infectivity and pathogen load at the within-host scale include [23] for malaria and [24] for human T lymphotropic virus, [32] for visceral leishmaniasis and chikungunya, and [46] for hepatitis B. Over the past decade, the importance of multi-scale modeling of infectious disease dynamics has been increasingly recognized, and many mathematical models linking within-host and between-host processes have been developed. The multi-scale models for influenza infections can be found in [18,22]. In [17], the within-host model is nested within a broader epidemiological model by linking the transmission rate of the infection or the additional host mortality rate to the dynamics of the within-host model. In studies such as [2,14], a nested multi-scale model (NMSM) is developed that considers the transmission rate at the intermediate host level as a linear function of viral load. A multi-scale model is developed and used to evaluate the effectiveness of health interventions acting at different time scales in [16]. Using a similar dynamic approach, there is considerable interest in linking disease dynamics at within-host and between-host levels, such as in the study of HIV and hepatitis C virus [11,30]. The multi-scale models for influenza infections can be found in [18,22]. Multi-scale mathematical modeling studies of infectious diseases have expanded the landscape of disease modeling and have the potential to more accurately describe disease dynamics [33]. A thorough understanding of the infectious disease transmission requires knowledge of the processes at different levels of the infectious disease and of the interplay between these levels. To obtain a clear idea of the dynamics of the disease, different time scale models need to be integrated [2,14,21].

Multi-scale models of the infectious disease systems integrate the within-host scale and the between-host scale. There are five main different categories of multi-scale models that can be developed at different levels of organization of an infectious disease system, which are: individual-based multi-scale models (IMSMs), NMSMs, embedded multi-scale models (EMSMs), hybrid multi-scale models (HMSMs), and coupled multi-scale models (CMSMs) [15]. In IMSMs, the within-host sub-model is used to describe the entire infectious disease system across both the within-host scale and between-host scale. In case of NMSMs, there is only unidirectional flow of information (only from within-host scale sub-model to between-host scale sub-model). There is never, any reciprocal feedback from the between-host scale sub-model back down to the within-host scale sub-model. In contrast, EMSMs is both a top-down and bottom-up modeling approach where both the within-host scale sub-model and the between-host sub-model influence each other. In all the aforementioned three categories of multi-scale models, the within-host scale and the between-host scale belonged to the same domain and is modeled in a homogeneous way using the same formalism. But in case of HMSMs, the within-host scale and the between-host scale may no longer be modeled in a homogeneous way. The HMSMs are formed based on the multi-domain integration framework. The details of these categories can be found in [15].

Multi-scale modeling of COVID-19 disease is still in its infancy, and efforts are being made in this direction. Some of the available articles on multi-scale modeling can be found in [1,4,36,45]. A multi-scale model would be extremely helpful in understanding the spread of COVID-19 infection and evaluating the efficacy of the interventions not only at the individual level but also at the population level. Therefore, in this study, we develop an NMSM that integrates within-host and between-host sub-models. As the importance of multi-scale modeling in disease dynamics is increasingly recognized, we believe that our study contributes to the growing knowledge on multi-scale modeling of COVID-19 disease.

This article is organized as follows: in Section 2, we develop an NMSM, study the stability and bifurcation analysis, and numerically illustrate the theoretical results obtained. We also analyze the sensitivity of R 0 {R}_{0} with respect to the model parameters and present two-parameter heat plots to identify the regions of stability. In Section 3, we conduct a comparative effectiveness study to evaluate the effectiveness of public health interventions for COVID-19. In Section 4, we provide the discussion and conclusions.

2
Multi-scale model

The multi-scale model that we develop describes COVID-19 disease dynamics across two different time scales, i.e., the within-host scale and the between-host scale. The within-host scale model tracks the density of the pathogens and also the state of the host’s defense mechanisms, while the between-host scale model is concerned with the transmission of the disease within the host population. The multi-scale model consists of seven variables, namely, susceptible cells ( U ) \left(U) , infected cells ( U * ) \left({U}^{* }) , viral load ( V ) \left(V) , and four between-host variables, namely, susceptible human population ( S ) \left(S) , infected human population ( I ) \left(I) , exposed human population ( E ) \left(E) , and recovered human population ( R ) \left(R) . We work with the following assumptions for the multi-scale model as in [16,36].

  • (a)

    The dynamics of the within-host scale variables are assumed to occur at a fast time scale s s so that U = U ( s ) U=U\left(s) , U * = U * ( s ) {U}^{* }={U}^{* }\left(s) , and V = V ( s ) V=V\left(s) , while the dynamics of the between-host scale variables is assumed to occur at a slow time scale t t so that S = S ( t ) S=S\left(t) , I = I ( t ) I=I\left(t) , E = E ( t ) E=E\left(t) , and R = R ( t ) R=R\left(t) . Because the infection obtains cleared within a few days, the value of V ( s ) V\left(s) is non-zero only for a short period of time. Due to this, the within-host dynamics is considered only for a short period of time. But because the infection remains for longer time at the population level, the between-host dynamics is considered for a longer period of time.

  • (b)

    The transmission rate β \beta and disease-induced death rate d d at the between-host scale are assumed to be functions of viral load.

  • (c)

    Immune response is captured in the model through the parameters x x and y y ; these parameters, respectively, denote the combined rates at which the infected cells and the virus are cleared by the release of cytokines and chemokines such as IL-6 TNF- α \alpha , INF- α \alpha , CCL5, CXCL8 and CXCL10 [10].

Based on the aforementioned assumptions, the multi-scale model is described by the following system of differential equations: (2.1) d U d s = ω k U ( s ) V ( s ) μ c U ( s ) , \frac{{\rm{d}}U}{{\rm{d}}s}=\omega -kU\left(s)V\left(s)-{\mu }_{c}U\left(s), (2.2) d U * d s = k U ( s ) V ( s ) x U * ( s ) μ c U * ( s ) , \frac{{\rm{d}}{U}^{* }}{{\rm{d}}s}=kU\left(s)V\left(s)-x{U}^{* }\left(s)-{\mu }_{c}{U}^{* }\left(s), (2.3) d V d s = α U * ( s ) y V ( s ) μ v V ( s ) , \frac{{\rm{d}}V}{{\rm{d}}s}=\alpha {U}^{* }\left(s)-yV\left(s)-{\mu }_{v}V\left(s), (2.4) d S d t = Λ β ( V ( s ) ) S ( t ) I ( t ) μ S ( t ) , \frac{{\rm{d}}S}{{\rm{d}}t}=\Lambda -\beta \left(V\left(s))S\left(t)I\left(t)-\mu S\left(t), (2.5) d E d t = β ( V ( s ) ) S ( t ) I ( t ) ( μ + π + γ 1 ) E ( t ) , \frac{{\rm{d}}E}{{\rm{d}}t}=\beta \left(V\left(s))S\left(t)I\left(t)-\left(\mu +\pi +{\gamma }_{1})E\left(t), (2.6) d I d t = π E ( t ) ( μ + γ 2 ) I ( t ) d ( V ( s ) ) I ( t ) , \frac{{\rm{d}}I}{{\rm{d}}t}=\pi E\left(t)-\left(\mu +{\gamma }_{2})I\left(t)-d\left(V\left(s))I\left(t), (2.7) d R d t = γ 1 E ( t ) + γ 2 I ( t ) μ R ( t ) . \frac{{\rm{d}}R}{{\rm{d}}t}={\gamma }_{1}E\left(t)+{\gamma }_{2}I\left(t)-\mu R\left(t). The within-host model (2.1)–(2.3) considered in this study is studied in detail by the authors in [10]. The meaning of each of the variables and parameters of the model (2.1)–(2.7) is given in Table 1.

Table 1

Meanings of the parameters

ParametersBiological meaning
ω \omega Natural birth rate of cells
Λ \Lambda Birth rate of human population
α \alpha Burst rate of the virus
μ \mu Natural death rate of human population
μ c {\mu }_{c} Natural death rate of cells
μ v {\mu }_{v} Natural death rate of virus
π \pi Infection rate of exposed population
k k Infection rate of susceptible cell
γ 1 , γ 2 {\gamma }_{1},{\gamma }_{2} Recovery rate of the exposed and infected human population
β \beta Transmission rate of the susceptible human population
x x Rate at which the infected cells are cleared by the individual immune response
y y Rate at which the virus particles are cleared by the individual immune response
d d Death rate of the infected human population

Based on the experimental observations of the impact of viral load on disease transmission [25] and disease-induced deaths, the linking of within-host and between-host sub-models is modeled by means of β = β ( V ( s ) ) \beta =\beta \left(V\left(s)) and d = d ( V ( s ) ) d=d\left(V\left(s)) . Though the exact functional relationship between viral load, transmission rate, and disease-induced death rate is not known [2], as in [2,14], we considered a linear form for the coupling functions β \beta and d d : β ( V ( s ) ) = β V ( s ) \beta \left(V\left(s))=\beta V\left(s) and d ( V ( s ) ) = d V ( s ) d\left(V\left(s))=dV\left(s) . We also observe that the first three equations of the between-host SEIR sub-model are independent of the recovered population R ( t ) R\left(t) . In similar lines to the studies done in [26,29], without loss of generality, we omit the last equation of the between-host SEIR sub-model. Taking β \beta and d d as linear functions of viral load and omitting the equation for R ( t ) R\left(t) in the between-host SEIR sub-model, the final multi-scale model for COVID-19 disease dynamics is given by the following set of equations: (2.8) d U d s = ω k U ( s ) V ( s ) μ c U ( s ) , \frac{{\rm{d}}U}{{\rm{d}}s}=\omega -kU\left(s)V\left(s)-{\mu }_{c}U\left(s), (2.9) d U * d s = k U ( s ) V ( s ) x U * ( s ) μ c U * ( s ) , \frac{{\rm{d}}{U}^{* }}{{\rm{d}}s}=kU\left(s)V\left(s)-x{U}^{* }\left(s)-{\mu }_{c}{U}^{* }\left(s), (2.10) d V d s = α U * ( s ) y V ( s ) μ v V ( s ) , \frac{{\rm{d}}V}{{\rm{d}}s}=\alpha {U}^{* }\left(s)-yV\left(s)-{\mu }_{v}V\left(s), (2.11) d S d t = Λ β V ( s ) S ( t ) I ( t ) μ S ( t ) , \frac{{\rm{d}}S}{{\rm{d}}t}=\Lambda -\beta V\left(s)S\left(t)I\left(t)-\mu S\left(t), (2.12) d E d t = β V ( s ) S ( t ) I ( t ) ( μ + π + γ 1 ) E ( t ) , \frac{{\rm{d}}E}{{\rm{d}}t}=\beta V\left(s)S\left(t)I\left(t)-\left(\mu +\pi +{\gamma }_{1})E\left(t), (2.13) d I d t = π E ( t ) ( μ + γ 2 ) I ( t ) d V ( s ) I ( t ) . \frac{{\rm{d}}I}{{\rm{d}}t}=\pi E\left(t)-\left(\mu +{\gamma }_{2})I\left(t)-dV\left(s)I\left(t).

2.1
Reduced multi-scale model for COVID-19 dynamics

The multi-scale model (2.8)–(2.13) is not that easy to analyze. The problem arises from the discrepancy between the time scales. The viral load V ( s ) V\left(s) at the within-host scale is a function of s s , while the dynamics of the between-host variables are assumed to occur at a slow time scale t t . To overcome these types of difficulties in multi-scale mathematical modeling studies of infectious diseases, a quantity called area under the viral load is defined using the within-host scale submodel [16,36]. In similar lines to the simplification done in [16,36], we simplify the multi-scale model (2.8)–(2.13) by defining the area under the viral load curve and use this quantity as a proxy for measuring the infectiousness of an individual host. We consider the within-host scale submodel from the multi-scale model (2.8)–(2.13) to derive the expression for the area under the viral load curve. From (2.8)–(2.13), the within-host submodel is given by the following system of differential equations: (2.14) d U d s = ω k U ( s ) V ( s ) μ c U ( s ) , \frac{{\rm{d}}U}{{\rm{d}}s}=\omega -kU\left(s)V\left(s)-{\mu }_{c}U\left(s), (2.15) d U * d s = k U ( s ) V ( s ) x U * ( s ) μ c U * ( s ) , \frac{{\rm{d}}{U}^{* }}{{\rm{d}}s}=kU\left(s)V\left(s)-x{U}^{* }\left(s)-{\mu }_{c}{U}^{* }\left(s), (2.16) d V d s = α U * ( s ) y V ( s ) μ v V ( s ) . \frac{{\rm{d}}V}{{\rm{d}}s}=\alpha {U}^{* }\left(s)-yV\left(s)-{\mu }_{v}V\left(s).

The viral load V ( s ) V\left(s) at the within-host scale provides the link between the within-host scale and the between-host scale. We use the within-host scale sub-model given by the model system (2.14)–(2.16) to estimate the individual host infectiousness. To derive an expression for the area under the viral load curve, we use the within-host sub-model (2.14)–(2.16). We denote the area under the viral load curve by N h {N}_{h} . The quantity N h {N}_{h} measures the total amount of COVID-19 virus produced by an infected human throughout the period of host infectivity, and thus can be considered a proxy for individual host infectivity [20]. Let d 1 {d}_{1} and d 2 {d}_{2} be the times at which the viral load takes on the value of the detection limit at the beginning and end of infection. Then, d 2 d 1 {d}_{2}-{d}_{1} can be considered as the duration of host infectivity. The amount of virus produced N h {N}_{h} , during the entire period of host infectiousness can be calculated from the within-host scale sub-model using the following formula: N h = d 1 d 2 V ( s ) d s . {N}_{h}=\underset{{d}_{1}}{\overset{{d}_{2}}{\int }}V\left(s){\rm{d}}s.

We obtain the expression for N h {N}_{h} in similar lines to the method discussed in [16]. Integrating equation (2.16) from d 1 {d}_{1} to d 2 {d}_{2} and using the definition of N h {N}_{h} , we obtain the following expressions: V ( d 2 ) V ( d 1 ) = α d 1 d 2 U * ( s ) d s ( y + μ v ) d 1 d 2 V ( s ) d s . V\left({d}_{2})-V\left({d}_{1})=\alpha \underset{{d}_{1}}{\overset{{d}_{2}}{\int }}{U}^{* }\left(s){\rm{d}}s-(y+{\mu }_{v})\underset{{d}_{1}}{\overset{{d}_{2}}{\int }}V\left(s){\rm{d}}s. Simplifying the aforementioned expression, we obtain (2.17) N h = α d 1 d 2 U * d s + V ( d 1 ) V ( d 2 ) y + μ v , {N}_{h}=\frac{\alpha {\int }_{{d}_{1}}^{{d}_{2}}{U}^{* }{\rm{d}}s+V\left({d}_{1})-V\left({d}_{2})}{y+{\mu }_{v}}, where U * {U}^{* } is the number of infected cells. The area under the viral load curve N h {N}_{h} given by equation (2.17) can be numerically calculated, and it gives a fixed value for the chosen set of parameter values. Now, the within-host scale sub-model (2.14)–(2.16) is reduced to a composed parameter N h {N}_{h} given by equation (2.17). This N h {N}_{h} replaces V ( s ) V\left(s) in the between-host scale sub-model as follows: (2.18) d S d t = Λ β N h S ( t ) I ( t ) μ S ( t ) , \frac{{\rm{d}}S}{{\rm{d}}t}=\Lambda -\beta {N}_{h}S\left(t)I\left(t)-\mu S\left(t), (2.19) d E d t = β N h S ( t ) I ( t ) ( μ + π + γ 1 ) E ( t ) , \frac{{\rm{d}}E}{{\rm{d}}t}=\beta {N}_{h}S\left(t)I\left(t)-\left(\mu +\pi +{\gamma }_{1})E\left(t), (2.20) d I d t = π E ( t ) ( μ + γ 2 ) I ( t ) d N h I ( t ) . \frac{{\rm{d}}I}{{\rm{d}}t}=\pi E\left(t)-\left(\mu +{\gamma }_{2})I\left(t)-d{N}_{h}I\left(t).

We note here that the entire within-host scale submodel is reduced to a single parameter N h {N}_{h} that depends on the within-host scale parameters. The reduced, simplified multi-scale model (2.18)–(2.20) is now on a single time scale t t and is easier to analyze. The reduced multi-scale model (2.18)–(2.20) is categorized as an NMSM according to the categorization of multi-scale models for infectious diseases [15] and is unidirectional, i.e., the within-host submodel influences the between-host submodel without mutual feedback. We study the impact of within-host dynamics on between-host dynamics via the composite parameter N h {N}_{h} .

2.2
Well-posedness of the model

The existence, the positivity, and the boundedness of the solutions of the proposed models (2.18)–(2.20) need to be proved to ensure that the model has a mathematical and biological meaning.

2.2.1
Positivity and boundedness

Positivity and boundedness of the solutions of Systems (2.18)–(2.20) are proved in similar lines to the method discussed in [3,29].

Positivity ̲ : \underline{{\bf{Positivity}}}{\boldsymbol{:}}

Lemma 2.1

Let S ( 0 ) 0 S\left(0)\ge 0 , E ( 0 ) 0 E\left(0)\ge 0 , and I ( 0 ) 0 I\left(0)\ge 0 , and then, the solutions S ( t ) , E ( t ) S\left(t),E\left(t) , and I ( t ) I\left(t) of Systems (2.18)–(2.20) are non-negative for all t 0 t\ge 0 .

Proof

Let x ( t ) = ( S ( t ) , E ( t ) , and I ( t ) ) x\left(t)=(S\left(t),E\left(t),\text{and}I\left(t)) be the solution of the system with the initial condition x 0 = ( S ( 0 ) , E ( 0 ) , and I ( 0 ) ) {x}_{0}=(S\left(0),E\left(0),\text{and}I\left(0)) . We assume that all the parameters of the model are positive. Because the quantity N h {N}_{h} measures the total amount of COVID-19 virus produced by an infected human, we consider N h {N}_{h} to be a positive parameter.

Now, using the continuity of solution, for all of S ( t ) , I ( t ) S\left(t),I\left(t) , and R ( t ) R\left(t) that have positive initial values at t = 0 t=0 , we have the existence of the solution on an interval ( 0 , t 0 ) \left(0,{t}_{0}) such that S ( t ) 0 S\left(t)\ge 0 , I ( t ) 0 I\left(t)\ge 0 , and R ( t ) 0 R\left(t)\ge 0 for 0 < t < t 0 0\lt t\lt {t}_{0} .

Now, let us say that we have t = t 1 0 t={t}_{1}\ge 0 such that S ( t 1 ) = 0 S\left({t}_{1})=0 and E ( t 1 ) 0 E\left({t}_{1})\ge 0 , I ( t 1 ) 0 I\left({t}_{1})\ge 0 . Then, from System (2.18), we find that at t = t 1 t={t}_{1} d S d t t = t 1 = Λ 0 . {\left.\frac{{\rm{d}}S}{{\rm{d}}t}\right|}_{t={t}_{1}}=\Lambda \ge 0. This positive derivative ensures that at any time, the solution reaches the axis, its derivative increases, and the function S ( t ) S\left(t) does not cross to negative part. This shows that S ( t ) S\left(t) remains non-negative for all t 0 t\ge 0 .

Similarly, using the same analysis, we can show that d E d t t = t 1 = β N h S ( t 1 ) I ( t 1 ) 0 , {\left.\frac{{\rm{d}}E}{{\rm{d}}t}\right|}_{t={t}_{1}}=\beta {N}_{h}S\left({t}_{1})I\left({t}_{1})\ge 0, d I d t t = t 1 = π E ( t 1 ) 0 . {\left.\frac{{\rm{d}}I}{{\rm{d}}t}\right|}_{t={t}_{1}}=\pi E\left({t}_{1})\ge 0.

Thus, we find that x ( t ) x\left(t) never crosses the axes S = 0 , I = 0 S=0,I=0 , and R = 0 R=0 when it touches them. Thus, for any positive initial conditions, the solutions S ( t ) , E ( t ) S\left(t),E\left(t) , and I ( t ) I\left(t) of Systems (2.18)–(2.20) remain non-negative for all t 0 t\ge 0 .

Boundedness ̲ : \underline{{\bf{Boundedness}}}{\boldsymbol{:}}

Let N ( t ) = S ( t ) + E ( t ) + I ( t ) N\left(t)=S\left(t)+E\left(t)+I\left(t)

Now, d N d t = d S d t + d E d t + d I d t = Λ μ ( S ( t ) + E ( t ) + I ( t ) ) γ 1 E γ 2 I d N h Λ μ N ( t ) . \begin{array}{rcl}\frac{{\rm{d}}N}{{\rm{d}}t}& =& \frac{{\rm{d}}S}{{\rm{d}}t}+\frac{{\rm{d}}E}{{\rm{d}}t}+\frac{{\rm{d}}I}{{\rm{d}}t}\\ \hspace{1em}& =& \Lambda -\mu \left(S\left(t)+E\left(t)+I\left(t))-{\gamma }_{1}E-{\gamma }_{2}I-d{N}_{h}\\ & \le & \Lambda -\mu N\left(t).\end{array} Therefore, d N d t + μ N ( t ) Λ . \frac{{\rm{d}}N}{{\rm{d}}t}+\mu N\left(t)\le \Lambda . The integrating factor is given by e μ t . {e}^{\mu t}. Therefore, after integration, we obtain

N ( t ) Λ μ + c e μ t N\left(t)\le \frac{\Lambda }{\mu }+c{e}^{-\mu t} , where c c is a constant. Now, as t t\to \infty , we obtain lim sup N(t) Λ μ . \hspace{0.1em}\text{lim sup N(t)}\hspace{0.1em}\le \frac{\Lambda }{\mu }. Thus, we have shown that the solutions of Systems (2.18)–(2.20) are ultimately bounded. Therefore, the biologically feasible region of Systems (2.18)–(2.20) is given by the following set: Ω = ( S ( t ) , E ( t ) , I ( t ) ) R + 3 : S ( t ) + E ( t ) + I ( t ) Λ μ , t 0 . \Omega =\left\{(S\left(t),E\left(t),I\left(t))\in {{\mathbb{R}}}_{+}^{3}:S\left(t)+E\left(t)+I\left(t)\le \frac{\Lambda }{\mu },\hspace{1em}t\ge 0\right\}.

We summarize the aforementioned discussion on boundedness by the following lemma.

Lemma 2.2

The set Ω = ( S ( t ) , E ( t ) , I ( t ) ) R + 3 : S ( t ) + E ( t ) + I ( t ) Λ μ , t 0 \Omega =\left\{(S\left(t),E\left(t),I\left(t))\in {{\mathbb{R}}}_{+}^{3}:S\left(t)+E\left(t)+I\left(t)\le \frac{\Lambda }{\mu },\hspace{1em}t\ge 0\right\} is a positive invariant and an attracting set for Systems (2.18)–(2.20).

2.2.2
Existence and uniqueness of solution

For the general first-order ordinary differential equation of the form (2.21) x ˙ = f ( t , x ) , x ( t 0 ) = x 0 . \dot{x}=f\left(t,x),\hspace{1em}x\left({t}_{0})={x}_{0}. One would have interest in knowing the answers to the following questions:

  • (i)

    Under what conditions, solution exists for System (2.21)?

  • (ii)

    Under what conditions, unique solution exists for System (2.21)?

We use Theorem A.1 from the appendix to establish the existence and uniqueness of the solution for our susceptible, exposed and infected models (2.18)–(2.20).

Let D denote the domain: t t 0 a , x x 0 b , x = ( x 1 , x 2 , , x n ) , x 0 = ( x 10 , , x n 0 ) , | t-{t}_{0}| \le a,| | x-{x}_{0}| | \le b,x=\left({x}_{1},{x}_{2},\ldots ,{x}_{n}),{x}_{0}=\left({x}_{10},\ldots ,{x}_{n0}), and f ( t , x ) f\left(t,x) satisfies the Lipschitz condition: (2.22) f ( t , x 2 ) f ( t , x 1 ) k x 2 x 1 . | | f\left(t,{x}_{2})-f\left(t,{x}_{1})| | \le k| | {x}_{2}-{x}_{1}| | . Then, we have the following theorem.

Theorem 2.1

(Existence of solution) Let D be the domain defined above such that (2.22) holds. Then, there exists a unique solution of model system of equations (2.18)–(2.20), which is bounded in the domain D.

Proof

Let (2.23) f 1 = Λ β N h S ( t ) I ( t ) μ S ( t ) , {f}_{1}=\Lambda -\beta {N}_{h}S\left(t)I\left(t)-\mu S\left(t), (2.24) f 2 = β N h S ( t ) I ( t ) ( μ + π + γ 1 ) E ( t ) , {f}_{2}=\beta {N}_{h}S\left(t)I\left(t)-\left(\mu +\pi +{\gamma }_{1})E\left(t), (2.25) f 3 = π E ( t ) ( μ + γ 2 ) I ( t ) d N h I ( t ) . {f}_{3}=\pi E\left(t)-\left(\mu +{\gamma }_{2})I\left(t)-d{N}_{h}I\left(t). We will show that f i x j , i , j = 1 , 2 , , n , \frac{\partial {f}_{i}}{\partial {x}_{j}},\hspace{1em}i,j=1,2,\ldots ,n, is continuous and bounded in the domain D.

From equation (2.23), we have f 1 S = β N h I μ , f 1 S = β N h I μ < , f 1 E = 0 , f 1 E < , f 1 I = β N h S , f 1 I = β N h S < . \begin{array}{rcl}\frac{\partial {f}_{1}}{\partial S}& =& -\beta {N}_{h}I-\mu ,\hspace{1em}\left|\frac{\partial {f}_{1}}{\partial S}\right|=| -\beta {N}_{h}I-\mu | \lt \infty ,\\ \frac{\partial {f}_{1}}{\partial E}& =& 0,\hspace{1em}\left|\frac{\partial {f}_{1}}{\partial E}\right|\lt \infty ,\\ \frac{\partial {f}_{1}}{\partial I}& =& -\beta {N}_{h}S,\hspace{1em}\left|\frac{\partial {f}_{1}}{\partial I}\right|=| -\beta {N}_{h}S| \lt \infty .\end{array}

Similarly, from equation (2.24), we have f 2 S = β N h I , f 2 S = β N h I < , f 2 E = μ π γ 1 , f 2 E = ( μ + π + γ 1 ) < , f 2 I = β N h S , f 2 I = β N h S < . \begin{array}{rcl}\frac{\partial {f}_{2}}{\partial S}& =& \beta {N}_{h}I,\hspace{1em}\left|\frac{\partial {f}_{2}}{\partial S}\right|=| \beta {N}_{h}I| \lt \infty ,\\ \frac{\partial {f}_{2}}{\partial E}& =& -\mu -\pi -{\gamma }_{1},\hspace{1em}\left|\frac{\partial {f}_{2}}{\partial E}\right|=| -\left(\mu +\pi +{\gamma }_{1})| \lt \infty ,\\ \frac{\partial {f}_{2}}{\partial I}& =& \beta {N}_{h}S,\hspace{1em}\left|\frac{\partial {f}_{2}}{\partial I}\right|=| \beta {N}_{h}S| \lt \infty .\end{array}

Finally, from (2.25), we have f 3 S = 0 , f 3 S < , f 3 E = π , f 3 E = π < , f 3 I = ( μ + γ 2 + d N h ) , f 3 I = ( μ + γ 2 + d N h ) < . \begin{array}{rcl}\frac{\partial {f}_{3}}{\partial S}& =& 0,\hspace{1em}\left|\frac{\partial {f}_{3}}{\partial S}\right|\lt \infty ,\\ \frac{\partial {f}_{3}}{\partial E}& =& \pi ,\hspace{1em}\left|\frac{\partial {f}_{3}}{\partial E}\right|=| \pi | \lt \infty ,\\ \frac{\partial {f}_{3}}{\partial I}& =& -\left(\mu +{\gamma }_{2}+d{N}_{h}),\hspace{1em}\left|\frac{\partial {f}_{3}}{\partial I}\right|=| -\left(\mu +{\gamma }_{2}+d{N}_{h})| \lt \infty .\end{array}

Hence, we have shown that all the partial derivatives are continuous and bounded. Therefore, Lipschitz condition (2.22) is satisfied. Hence, by Theorem 2.1, there exists a unique solution of Systems (2.18)–(2.20) in the region D D .□

2.3
Stability analysis

The basic reproduction number denoted by R 0 {R}_{0} that gives the average number of secondary cases per primary case is calculated using the next-generation matrix method [13], and the expression for R 0 {R}_{0} for Systems (2.18)–(2.20) is given by (2.26) R 0 = β N h π Λ μ ( μ + π + γ 1 ) ( μ + γ 2 + d N h ) {{\bf{R}}}_{0}=\frac{\beta {N}_{h}\pi \Lambda }{\mu \left(\mu +\pi +{\gamma }_{1})\left(\mu +{\gamma }_{2}+d{N}_{h})}

Systems (2.18)–(2.20) admit two equilibria, namely, the infection-free equilibrium E 0 = Λ μ , 0 , 0 {E}_{0}=\left(\phantom{\rule[-0.75em]{}{0ex}},\frac{\Lambda }{\mu },0,0\right) and the infected equilibrium E 1 = ( S * , E * , I * ) {E}_{1}=\left({S}^{* },{E}^{* },{I}^{* }) , where

S * = Λ ( β N h I * + μ ) , {S}^{* }=\frac{\Lambda }{\left(\beta {N}_{h}{I}^{* }+\mu )}, E * = ( μ + γ 2 + d N h ) I * π , {E}^{* }=\frac{\left(\mu +{\gamma }_{2}+d{N}_{h}){I}^{* }}{\pi }, I * = μ ( R 0 1 ) β N h . {I}^{* }=\frac{\mu \left({R}_{0}-1)}{\beta {N}_{h}}.

Since negative population does not make sense, the existence condition for the infected equilibrium point E 1 {E}_{1} is that R 0 > 1 {R}_{0}\gt 1 .

2.3.1
Stability analysis of E 0 {E}_{0}

We analyze the stability of equilibrium points E 0 {E}_{0} . This is done based on the nature of the eigenvalues of the Jacobian matrix evaluated at E 0 {E}_{0} .

The Jacobian matrix of Systems (2.18)–(2.20) at the infection-free equilibrium E 0 {E}_{0} is given by J E 0 = μ 0 β N h Λ μ 0 ( μ + π + γ 1 ) β N h Λ μ 0 π ( μ + γ 2 + d N h ) . {J}_{{E}_{0}}=\left(\begin{array}{ccc}-\mu & 0& \frac{-\beta {N}_{h}\Lambda }{\mu }\\ 0& -\left(\mu +\pi +{\gamma }_{1})& \frac{\beta {N}_{h}\Lambda }{\mu }\\ 0& \pi & -\left(\mu +{\gamma }_{2}+d{N}_{h})\end{array}\right).

The characteristic equation of J E 0 {J}_{{E}_{0}} is given by (2.27) ( μ λ ) ( λ 2 + ( 2 μ + π + γ 1 + γ 2 + d N h ) λ ( R 0 1 ) ( μ + π + γ 1 ) ( μ + γ 2 + d N h ) ) . \left(-\mu -\lambda )({\lambda }^{2}+\left(2\mu +\pi +{\gamma }_{1}+{\gamma }_{2}+d{N}_{h})\lambda -\left({R}_{0}-1)\left(\mu +\pi +{\gamma }_{1})\left(\mu +{\gamma }_{2}+d{N}_{h})). One of the eigenvalues of characteristic equation ( 2.27 ) \left(2.27) is μ -\mu and the other two are the roots of the following quadratic equation: (2.28) λ 2 + ( 2 μ + π + γ 1 + γ 2 + d N h ) λ ( R 0 1 ) ( μ + π + γ 1 ) ( μ + γ 2 + d N h ) . {\lambda }^{2}+\left(2\mu +\pi +{\gamma }_{1}+{\gamma }_{2}+d{N}_{h})\lambda -\left({R}_{0}-1)\left(\mu +\pi +{\gamma }_{1})\left(\mu +{\gamma }_{2}+d{N}_{h}). We see that when R 0 < 1 {R}_{0}\lt 1 , both the eigenvalues of equation (2.28) are negative. Therefore, E 0 {E}_{0} remains locally asymptotically stable whenever R 0 < 1 {R}_{0}\lt 1 . When R 0 > 1 {R}_{0}\gt 1 , the quadratic equation ( 2.28 ) \left(2.28) has one positive and one negative root. Therefore, the characteristic equation (2.27) has two negative and one positive root. Hence, E 0 {E}_{0} becomes unstable in this case. We summarize the local asymptotic stability of infection-free equilibrium E 0 {E}_{0} in the following theorem.

Theorem 2.2

The infection-free equilibrium point E 0 {E}_{0} of Systems (2.18)–(2.20) is locally asymptotically stable provided R 0 < 1 {R}_{0}\lt 1 . If R 0 {R}_{0} crosses unity, E 0 {E}_{0} loses its stability and becomes unstable.

Global stability of E 0 ̲ \underline{{\bf{Global}}\hspace{0.33em}{\bf{stability\; of}}\hspace{0.33em}{E}_{0}}

To establish the global stability of the infection-free equilibrium E 0 {E}_{0} , we make use of the method discussed in Castillo-Chavez et al. [7]. The general form of the theorem is stated in Appendix.

Theorem 2.3

The infection-free equilibrium point E 0 {E}_{0} of Systems (2.18)–(2.20) is globally asymptotically stable whenever R 0 < 1 . {R}_{0}\lt 1.

Proof

We will prove the global stability of E 0 = ( ω μ , 0 , 0 ) {E}_{0}=\left(\frac{\omega }{\mu },0,0) of Systems (2.18)–(2.20) by showing that Systems (2.18)–(2.20) can be written in the general form stated in Theorem A.2 (Appendix) and both the conditions A 1 {A}_{1} and A 2 {A}_{2} of Theorem A.2 are satisfied.

Comparing the general system to Systems (2.18)–(2.20), the functions F F and G G are given by

F ( X , Y ) = Λ β N h S I μ S , F\left(X,Y)=\Lambda -\beta {N}_{h}SI-\mu S, G ( X , Y ) = ( β N h S I ( m u + π + γ 1 ) E , π E ( μ + γ 2 + d N h ) I ) , G\left(X,Y)=(\beta {N}_{h}SI-\left(mu+\pi +{\gamma }_{1})E,\hspace{0.33em}\pi E-\left(\mu +{\gamma }_{2}+d{N}_{h})I), where X = S X=S and Y = ( E , I ) Y=\left(E,I) .

The infection-free equilibrium point is U 0 = ( X 0 , 0 ¯ ) , {U}_{0}=\left({X}_{0},\bar{0}), where X 0 = Λ μ and 0 ¯ = ( 0 , 0 ) . {X}_{0}=\frac{\Lambda }{\mu }\hspace{1.0em}\hspace{0.1em}\text{and}\hspace{0.1em}\hspace{1.0em}\bar{0}=\left(0,0). From the stability analysis of E 0 {E}_{0} , we know that U 0 {U}_{0} is locally asymptotically stable iff R 0 < 1 {R}_{0}\lt 1 . Clearly, we see that G ( X , 0 ¯ ) = ( 0 , 0 ¯ ) G\left(X,\bar{0})=\left(0,\bar{0}) . Now, we show that X 0 = ( Λ μ ) {X}_{0}=\left(\frac{\Lambda }{\mu }) is globally asymptotically stable for the subsystem (2.29) d S d t = F ( S , 0 ¯ ) = ω μ S . \frac{{\rm{d}}S}{{\rm{d}}t}=F\left(S,\bar{0})=\omega -\mu S.

The integrating factor is e μ t {e}^{\mu t} , and therefore, after performing integration on equation (2.29), we obtain S ( t ) e μ t = Λ e μ t μ + c . S\left(t){e}^{\mu t}=\frac{\Lambda {e}^{\mu t}}{\mu }+c. As t t\to \infty , we obtain S ( t ) = ω μ , S\left(t)=\frac{\omega }{\mu }, which is independent of c. This independency implies that X 0 = Λ μ 1 {X}_{0}=\frac{\Lambda }{{\mu }_{1}} is globally asymptotically stable for the subsystem d S d t = Λ μ S \frac{{\rm{d}}S}{{\rm{d}}t}=\Lambda -\mu S . So, the assumption A 1 {A}_{1} is satisfied.

Now, we will show that assumption A 2 {A}_{2} holds. First, we will find the matrix A A . As per the theorem, A = D Y G ( X , Y ) A={D}_{Y}G\left(X,Y) at X = X 0 X={X}_{0} and Y = 0 ¯ Y=\bar{0} . Now, D Y G ( X , Y ) = ( μ + π + γ 1 ) β N h S π ( μ + γ 2 + d N h ) . {D}_{Y}G\left(X,Y)=\left[\begin{array}{cc}-\left(\mu +\pi +{\gamma }_{1})& \beta {N}_{h}S\\ \pi & -\left(\mu +{\gamma }_{2}+d{N}_{h})\end{array}\right].

At X = X 0 X={X}_{0} and Y = 0 ¯ Y=\bar{0} , we obtain A = ( μ + π + γ 1 ) β N h Λ μ π ( μ + γ 2 + d N h ) . A=\left[\begin{array}{cc}-\left(\mu +\pi +{\gamma }_{1})& \frac{\beta {N}_{h}\Lambda }{\mu }\\ \pi & -\left(\mu +{\gamma }_{2}+d{N}_{h})\end{array}\right]. Clearly, matrix A A has non-negative off-diagonal elements. Hence, A A is a M-matrix. Using G ^ ( X , Y ) = A Y G ( X , Y ) \widehat{G}\left(X,Y)=AY-G\left(X,Y) , we obtain G ^ ( X , Y ) = G 1 ^ ( X , Y ) G 2 ^ ( X , Y ) = β N h I Λ μ S 0 \widehat{G}\left(X,Y)=\left[\begin{array}{c}\widehat{{G}_{1}}\left(X,Y)\\ \widehat{{G}_{2}}\left(X,Y)\end{array}\right]=\left[\begin{array}{c}\beta {N}_{h}I\left(\frac{\Lambda }{\mu }-S\right)\\ 0\end{array}\right] Hence, G 1 ^ ( X , Y ) = β N h I ( Λ μ S ) 0 \widehat{{G}_{1}}\left(X,Y)=\beta {N}_{h}I\left(\frac{\Lambda }{\mu }-S)\ge 0 because S ( t ) Λ μ S\left(t)\le \frac{\Lambda }{\mu } and G 2 ^ ( X , Y ) = 0 \widehat{{G}_{2}}\left(X,Y)=0 .

Thus, both Assumptions A 1 {A}_{1} and A 2 {A}_{2} are satisfied, and therefore, infection-free equilibrium point E 0 {E}_{0} is globally asymptotically stable provided R 0 < 1 {R}_{0}\lt 1 .□

2.3.2
Stability analysis of E 1 {E}_{1}

The Jacobian matrix of Systems (2.18)–(2.20) at E 1 {E}_{1} is given by J = ( β N h I * + μ ) 0 β N h S β N h I * ( μ + π + γ 1 ) β N h S * 0 π ( μ + γ 2 + d N h ) . J=\left(\begin{array}{ccc}-\left(\beta {N}_{h}{I}^{* }+\mu )& 0& -\beta {N}_{h}S\\ \beta {N}_{h}{I}^{* }& -\left(\mu +\pi +{\gamma }_{1})& \beta {N}_{h}{S}^{* }\\ 0& \pi & -\left(\mu +{\gamma }_{2}+d{N}_{h})\end{array}\right).

The characteristic equation of the Jacobian J J evaluated at E 1 {E}_{1} is given by (2.30) λ 3 + A 1 λ 2 + B 1 λ + C 1 = 0 , {\lambda }^{3}+{A}_{1}{\lambda }^{2}+{B}_{1}\lambda +{C}_{1}=0, where A 1 = 3 μ + π + β N h I * + γ 1 + γ 2 + d N h , {A}_{1}=3\mu +\pi +\beta {N}_{h}{I}^{* }+{\gamma }_{1}+{\gamma }_{2}+d{N}_{h}, B 1 = ( μ + β N h I * ) ( 2 μ + π + γ 1 + γ 2 + d N h ) + ( μ + π + γ 1 ) ( μ + γ 2 + d N h ) β N h π S * , {B}_{1}=\left(\mu +\beta {N}_{h}{I}^{* })\left(2\mu +\pi +{\gamma }_{1}+{\gamma }_{2}+d{N}_{h})+\left(\mu +\pi +{\gamma }_{1})\left(\mu +{\gamma }_{2}+d{N}_{h})-\beta {N}_{h}\pi {S}^{* }, C 1 = ( μ + β N h I * ) ( ( μ + π + γ 1 ) ( μ + γ 2 + d N h ) β N h π S * ) + β 2 N h 2 S * I * π . {C}_{1}=\left(\mu +\beta {N}_{h}{I}^{* })(\left(\mu +\pi +{\gamma }_{1})\left(\mu +{\gamma }_{2}+d{N}_{h})-\beta {N}_{h}\pi {S}^{* })+{\beta }^{2}{N}_{h}^{2}{S}^{* }{I}^{* }\pi .

Clearly, A 1 > 0 {A}_{1}\gt 0 . By the Routh-Hurwitz criterion, all the roots of characteristic equation (2.30) are negative iff C 1 > 0 {C}_{1}\gt 0 and A 1 B 1 C 1 > 0 {A}_{1}{B}_{1}-{C}_{1}\gt 0 .

Simplifying the expression for C 1 {C}_{1} , we obtain C 1 = μ ( μ + π + γ 1 ) ( μ + γ 2 + d N h ) ( R 0 1 ) . {C}_{1}=\mu \left(\mu +\pi +{\gamma }_{1})\left(\mu +{\gamma }_{2}+d{N}_{h})\left({R}_{0}-1). Therefore, C 1 > 0 {C}_{1}\gt 0 iff R 0 > 1 {R}_{0}\gt 1 . Hence, we conclude that the infected equilibrium point E 1 {E}_{1} exists and remains locally asymptotically stable provided R 0 > 1 {R}_{0}\gt 1 and ( A 1 B 1 C 1 ) > 0 \left({A}_{1}{B}_{1}-{C}_{1})\gt 0 . In the following theorem, we summarize the aforementioned discussion on the stability of E 1 {E}_{1} .

Theorem 2.4

A unique infected equilibrium point E 1 {E}_{1} exists for Systems (2.18)–(2.20) and remains locally asymptotically stable provided that the following conditions are satisfied:

  • (i)

    R 0 > 1 {R}_{0}\gt 1 .

  • (ii)

    ( A 1 B 1 C 1 ) > 0 \left({A}_{1}{B}_{1}-{C}_{1})\gt 0 .

2.4
Bifurcation analysis

We use the method given by Castillo-Chavez and Song in [8] to do the bifurcation analysis.

Applying Theorem A.3 (appendix) to the system ( 2.18 ) ( 2.20 ) ̲ : \underline{{\bf{Applying}}\hspace{0.33em}{\bf{Theorem}}\hspace{0.33em}{\bf{A.3}}\hspace{0.33em}{\bf{(appendix)}}\hspace{0.33em}{\bf{to}}\hspace{0.33em}{\bf{the}}\hspace{0.33em}{\bf{system}}\hspace{0.33em}\left(2.18)\hspace{0.1em}\text{&#x2013;}\hspace{0.1em}\left(2.20)}:

In our case, we have x = ( S , E , I ) R 3 x=\left(S,E,I)\in {{\mathbb{R}}}^{3} , where x 1 = S {x}_{1}=S , x 2 = E {x}_{2}=E , and x 3 = I {x}_{3}=I . Let us consider β \beta (transmission rate of the infection) to be the bifurcation parameter.

We know that R 0 = β N h Λ π μ ( μ + π + γ 1 ) ( μ + γ 2 + d N h ) . {R}_{0}=\frac{\beta {N}_{h}\Lambda \pi }{\mu \left(\mu +\pi +{\gamma }_{1})\left(\mu +{\gamma }_{2}+d{N}_{h})}. Therefore, we have β = R 0 μ ( μ + π + γ 1 ) ( μ + γ 2 + d N h ) β N h Λ π . \beta =\frac{{R}_{0}\mu \left(\mu +\pi +{\gamma }_{1})\left(\mu +{\gamma }_{2}+d{N}_{h})}{\beta {N}_{h}\Lambda \pi }.

Let β = β * \beta ={\beta }^{* } at R 0 = 1 {R}_{0}=1 . So, we have β * = μ ( μ + π + γ 1 ) ( μ + γ 2 + d N h ) β N h Λ π . {\beta }^{* }=\frac{\mu \left(\mu +\pi +{\gamma }_{1})\left(\mu +{\gamma }_{2}+d{N}_{h})}{\beta {N}_{h}\Lambda \pi }.

With x = ( x 1 , x 2 , x 3 ) = ( S , I , V ) x=\left({x}_{1},{x}_{2},{x}_{3})=\left(S,I,V) Systems (2.18)–(2.20) can be written as follows: d x 1 d t = Λ β N h x 1 x 3 μ x 1 = f 1 , \frac{{\rm{d}}{x}_{1}}{{\rm{d}}t}=\Lambda -\beta {N}_{h}{x}_{1}{x}_{3}-\mu {x}_{1}={f}_{1}, d x 2 d t = β N h x 1 x 3 ( μ + π + γ 1 ) x 2 = f 2 , \frac{{\rm{d}}{x}_{2}}{{\rm{d}}t}=\beta {N}_{h}{x}_{1}{x}_{3}-\left(\mu +\pi +{\gamma }_{1}){x}_{2}={f}_{2}, d x 3 d t = π x 2 ( μ + γ 2 + d N h ) x 3 = f 3 . \frac{{\rm{d}}{x}_{3}}{{\rm{d}}t}=\pi {x}_{2}-\left(\mu +{\gamma }_{2}+d{N}_{h}){x}_{3}\hspace{1.0em}={f}_{3}.

The infection-free equilibrium point E 0 {E}_{0} is given by x * = Λ μ , 0 , 0 = ( x 1 * , x 2 * , x 3 * ) . {x}^{* }=\left(\frac{\Lambda }{\mu },0,0\right)=\left({x}_{1}^{* },{x}_{2}^{* },{x}_{3}^{* }).

Clearly, f ( x * , β ) = 0 , β R f\left({x}^{* },\beta )=0,\hspace{0.33em}\forall \beta \in {\mathbb{R}} , where f = ( f 1 , f 2 , f 3 ) f=({f}_{1},{f}_{2},{f}_{3}) . Let D x f ( x * , β * ) {D}_{x}f\left({x}^{* },{\beta }^{* }) denote the Jacobian matrix of the aforementioned system at the equilibrium point x * {x}^{* } and R 0 = 1 {R}_{0}=1 . Now, we see that D x f ( x * , β * ) = μ 0 β * N h Λ μ 0 ( μ + π + γ 1 ) β * N h Λ μ 0 π ( μ + γ 2 + d N h ) . {D}_{x}f\left({x}^{* },{\beta }^{* })=\left[\begin{array}{ccc}-\mu & 0& \frac{-{\beta }^{* }{N}_{h}\Lambda }{\mu }\\ 0& -\left(\mu +\pi +{\gamma }_{1})& \frac{{\beta }^{* }{N}_{h}\Lambda }{\mu }\\ 0& \pi & -\left(\mu +{\gamma }_{2}+d{N}_{h})\end{array}\right]. The characteristic polynomial of the aforementioned matrix D x f ( x * , β * ) {D}_{x}f\left({x}^{* },{\beta }^{* }) is given by (2.31) ( μ λ ) ( ( μ + π + γ 1 ) + λ ) ( ( μ + γ 2 + d N h ) + λ ) β * N h Λ π μ = 0 . \left(-\mu -\lambda )\left[\left(\left(\mu +\pi +{\gamma }_{1})+\lambda )\left(\left(\mu +{\gamma }_{2}+d{N}_{h})+\lambda )-\left(\frac{{\beta }^{* }{N}_{h}\Lambda \pi }{\mu }\right)\right]=0.

Hence, we obtain the first eigenvalue of (2.31) as λ 1 = μ < 0 . {\lambda }_{1}=-\mu \lt 0.

The other eigenvalues λ 2 , 3 {\lambda }_{2,3} of (2.31) are the solutions of the following equation: (2.32) λ 2 + ( 2 μ + π + γ 1 + γ 2 + d N h ) λ + ( μ + π + γ 1 ) ( μ + γ 2 + d N h ) β * N h π Λ μ = 0 . {\lambda }^{2}+(2\mu +\pi +{\gamma }_{1}+{\gamma }_{2}+d{N}_{h})\lambda +\left(\mu +\pi +{\gamma }_{1})\left(\mu +{\gamma }_{2}+d{N}_{h})-\frac{{\beta }^{* }{N}_{h}\pi \Lambda }{\mu }=0.

Substituting the expression for β * {\beta }^{* } in (2.32), we obtain (2.33) λ 2 + ( 2 μ + π + γ 1 + γ 2 + d N h ) λ = 0 . {\lambda }^{2}+(2\mu +\pi +{\gamma }_{1}+{\gamma }_{2}+d{N}_{h})\lambda =0.

The eigenvalues of (2.33) are λ 2 = 0 {\lambda }_{2}=0 and λ 3 = ( 2 μ + π + γ 1 + γ 2 + d N h ) {\lambda }_{3}=-\left(2\mu +\pi +{\gamma }_{1}+{\gamma }_{2}+{\rm{d}}{N}_{h}) .

Hence, the matrix D x f ( x * , β * ) {D}_{x}f\left({x}^{* },{\beta }^{* }) has zero as its simple eigenvalue and all other eigenvalues with negative real parts. Thus, Condition 1 of Theorem A.3 (appendix) is satisfied.

Next, for proving Condition 2, we need to find the right and left eigenvectors of the zero eigenvalue ( λ 2 {\lambda }_{2} ). Let us denote the right and left eigen vectors by w {\boldsymbol{w}} and v {\boldsymbol{v}} , respectively. To find w w , we use ( D x f ( x * , β * ) λ 2 I d ) w = 0 \left({D}_{x}f\left({x}^{* },{\beta }^{* })-{\lambda }_{2}{I}_{d})w=0 , which implies that

μ 0 β * N h Λ μ 0 ( μ + π + γ 1 ) β * N h Λ μ 0 π ( μ + γ 2 + d N h ) w 1 w 2 w 3 = 0 0 0 , \left[\begin{array}{ccc}-\mu & 0& \frac{-{\beta }^{* }{N}_{h}\Lambda }{\mu }\\ 0& -\left(\mu +\pi +{\gamma }_{1})& \frac{{\beta }^{* }{N}_{h}\Lambda }{\mu }\\ 0& \pi & -\left(\mu +{\gamma }_{2}+d{N}_{h})\end{array}\right]\left[\begin{array}{c}{w}_{1}\\ {w}_{2}\\ {w}_{3}\end{array}\right]=\left[\begin{array}{c}0\\ 0\\ 0\end{array}\right], where w = ( w 1 , w 2 , w 3 ) T w={\left({w}_{1},{w}_{2},{w}_{3})}^{T} . As a result, we obtain the system of simultaneous equations as follows: (2.34) μ w 1 β * N h Λ μ w 3 = 0 , -\mu {w}_{1}-\frac{{\beta }^{* }{N}_{h}\Lambda }{\mu }{w}_{3}=0, (2.35) ( μ + π + γ 1 ) w 2 + β * N h Λ μ w 3 = 0 , -\left(\mu +\pi +{\gamma }_{1}){w}_{2}+\frac{{\beta }^{* }{N}_{h}\Lambda }{\mu }{w}_{3}=0, (2.36) π w 2 ( μ + γ 2 + d N h ) w 3 = 0 . \pi {w}_{2}-\left(\mu +{\gamma }_{2}+d{N}_{h}){w}_{3}=0.

By choosing w 3 = μ {w}_{3}=\mu in the aforementioned simultaneous equations (2.34)–(2.36), we obtain w 2 = β * N h Λ ( μ + π + γ 1 ) and w 1 = β * N h Λ μ . {w}_{2}=\frac{{\beta }^{* }{N}_{h}\Lambda }{\left(\mu +\pi +{\gamma }_{1})}\hspace{0.33em}\hspace{0.33em}\hspace{0.33em}\hspace{0.1em}\text{and}\hspace{0.1em}\hspace{0.33em}\hspace{0.33em}\hspace{0.33em}{w}_{1}=-\frac{{\beta }^{* }{N}_{h}\Lambda }{\mu }.

Therefore, the right eigen vector of zero eigenvalue is given by w = β * N h Λ μ , β * N h Λ ( μ + π + γ 1 ) , μ . {\boldsymbol{w}}=\left(-\frac{{{\boldsymbol{\beta }}}^{* }{{\boldsymbol{N}}}_{{\boldsymbol{h}}}{\boldsymbol{\Lambda }}}{{\boldsymbol{\mu }}},\hspace{0.33em}\frac{{{\boldsymbol{\beta }}}^{* }{{\boldsymbol{N}}}_{{\boldsymbol{h}}}{\boldsymbol{\Lambda }}}{\left({\boldsymbol{\mu }}+{\boldsymbol{\pi }}+{{\boldsymbol{\gamma }}}_{{\boldsymbol{1}}})},\hspace{0.33em}\mu \right).

Similarly, to find the left eigenvector v v , we use v ( D x f ( x * , β * ) λ 2 I d ) = 0 v\left({D}_{x}f\left({x}^{* },{\beta }^{* })-{\lambda }_{2}{I}_{d})=0 , which implies that v 1 v 2 v 3 μ 0 β * N h Λ μ 0 ( μ + π + γ 1 ) β * N h Λ μ 0 π ( μ + γ 2 + d N h ) = 0 0 0 , \left[\begin{array}{ccc}{v}_{1}& {v}_{2}& {v}_{3}\end{array}\right]\left[\begin{array}{ccc}-\mu & 0& \frac{-{\beta }^{* }{N}_{h}\Lambda }{\mu }\\ 0& -\left(\mu +\pi +{\gamma }_{1})& \frac{{\beta }^{* }{N}_{h}\Lambda }{\mu }\\ 0& \pi & -\left(\mu +{\gamma }_{2}+d{N}_{h})\end{array}\right]=\left[\begin{array}{ccc}0& 0& 0\end{array}\right], where v = ( v 1 , v 2 , v 3 ) v=\left({v}_{1},{v}_{2},{v}_{3}) . The simultaneous equations obtained thereby are as follows: (2.37) μ v 1 = 0 , -\mu {v}_{1}=0, (2.38) ( μ + π + γ 1 ) v 2 + π v 3 = 0 , -\left(\mu +\pi +{\gamma }_{1}){v}_{2}+\pi {v}_{3}=0, (2.39) β * N h Λ μ v 1 + β * N h Λ μ v 2 ( μ + γ 2 + d N h ) v 3 = 0 . \frac{-{\beta }^{* }{N}_{h}\Lambda }{\mu }{v}_{1}+\frac{{\beta }^{* }{N}_{h}\Lambda }{\mu }{v}_{2}-\left(\mu +{\gamma }_{2}+d{N}_{h}){v}_{3}=0. Therefore, solving the aforementioned simultaneous equations (2.37)–(2.39), we obtain v 1 = 0 {v}_{1}=0 .

By choosing v 2 = 1 {v}_{2}=1 , we obtain v 3 = β * N h Λ ( μ ( μ + γ 2 + d N h ) ) . {v}_{3}=\frac{{\beta }^{* }{N}_{h}\Lambda }{\left(\mu \left(\mu +{\gamma }_{2}+d{N}_{h}))}.

Hence, the left eigen vector is given by v = 0 , 1 , β * N h Λ ( μ ( μ + γ 2 + d N h ) ) . v=\left(0,1,\frac{{\beta }^{* }{N}_{h}\Lambda }{\left(\mu \left(\mu +{\gamma }_{2}+d{N}_{h}))}\right).

Now, we need to find a a and b b . As per Theorem 2.7, a a and b b are given by

a = k , i , j = 1 3 v k u i u j 2 f k x i x j ( x * , β * ) , a=\mathop{\sum }\limits_{k,i,j=1}^{3}\left[{v}_{k}{u}_{i}{u}_{j}\left(\frac{{\partial }^{2}{f}_{k}}{\partial {x}_{i}\partial {x}_{j}}\left({x}^{* },{\beta }^{* })\right)\right], b = k , i = 1 3 v k u i 2 f k x i β ( x * , β * ) . b=\mathop{\sum }\limits_{k,i=1}^{3}\left[{v}_{k}{u}_{i}\left(\frac{{\partial }^{2}{f}_{k}}{\partial {x}_{i}\partial \beta }\left({x}^{* },{\beta }^{* })\right)\right].

Expanding the summation in the expression for a a , it reduces to

a = w 1 w 3 2 f 2 x 1 x 3 + w 3 w 1 2 f 2 x 3 x 1 , a={w}_{1}{w}_{3}\frac{{\partial }^{2}{f}_{2}}{\partial {x}_{1}\partial {x}_{3}}+{w}_{3}{w}_{1}\frac{{\partial }^{2}{f}_{2}}{\partial {x}_{3}\partial {x}_{1}}, where partial derivatives are found at ( x * , β * ) \left({x}^{* },{\beta }^{* }) . Now, 2 f 2 x 1 x 3 ( x * , β * ) = β * N h and 2 f 2 x 3 x 1 ( x * , β * ) = β * N h . \frac{{\partial }^{2}{f}_{2}}{\partial {x}_{1}\partial {x}_{3}}\left({x}^{* },{\beta }^{* })={\beta }^{* }{N}_{h}\hspace{1.0em}{\rm{and}}\hspace{1em}\frac{{\partial }^{2}{f}_{2}}{\partial {x}_{3}\partial {x}_{1}}\left({x}^{* },{\beta }^{* })={\beta }^{* }{N}_{h}.

Substituting these partial derivatives along with w w in the expression of a a , we obtain a = 2 β * 2 N h 2 Λ < 0 . a=-2{\beta }^{* 2}{N}_{h}^{2}\Lambda \lt 0.

Next, expanding the summation in the expression for b b , we obtain b = v 2 w 2 2 f 2 x 1 β ( x * , β * ) + v 2 w 3 2 f 2 x 3 β ( x * , β * ) . b={v}_{2}{w}_{2}\left(\frac{{\partial }^{2}{f}_{2}}{\partial {x}_{1}\partial \beta }\left({x}^{* },{\beta }^{* })\right)+{v}_{2}{w}_{3}\left(\frac{{\partial }^{2}{f}_{2}}{\partial {x}_{3}\partial \beta }\left({x}^{* },{\beta }^{* })\right).

Now, 2 f 2 x 3 β ( x * , β * ) = N h λ μ , \frac{{\partial }^{2}{f}_{2}}{\partial {x}_{3}\partial \beta }\left({x}^{* },{\beta }^{* })=\frac{{N}_{h}\lambda }{\mu }, 2 f 2 x 1 β ( x * , β * ) = 0 . \frac{{\partial }^{2}{f}_{2}}{\partial {x}_{1}\partial \beta }\left({x}^{* },{\beta }^{* })=0. Substituting in the expression of b b , we obtain b = N h Λ > 0 . b={N}_{h}\Lambda \gt 0.

Hence, a < 0 a\lt 0 and b > 0 b\gt 0 . We note that Condition (iv) of Theorem A.3 (appendix) is satisfied. Hence, we conclude that the system undergoes bifurcation at β = β * \beta ={\beta }^{* } , implying R 0 = 1 {R}_{0}=1 .

Thus, we conclude that when R 0 < 1 {R}_{0}\lt 1 , there exists a unique infection-free equilibrium, which is globally asymptotically stable, and negative infected equilibrium which is unstable. Since negative values of population are not practical, we ignore it in this case. Furthermore, as R 0 {R}_{0} crosses unity from below, the infection-free equilibrium point loses its stable nature and become unstable, the bifurcation point being at β = β * \beta ={\beta }^{* } implying R 0 = 1 {R}_{0}=1 and there appears a positive locally asymptotically stable infected equilibrium point. There is an exchange of stability between infection-free equilibrium and infected equilibrium at R 0 = 1 {R}_{0}=1 . Hence, a forward bifurcation (trans-critical bifurcation) takes place at the break point β = β * \beta ={\beta }^{* } . We summarize the aforementioned discussion on bifurcation by the following theorem.

Theorem 2.5

As R 0 {R}_{0} crosses unity, the infection-free equilibrium changes its stability from stable to unstable and there exists a locally asymptotically infected equilibrium when R 0 > 1 {R}_{0}\gt 1 , i.e., direction of bifurcation is forward (transcritical) at R 0 > 1 {R}_{0}\gt 1 .

From the expression of R 0 {R}_{0} , the condition R 0 = 1 {R}_{0}=1 can be rewritten in terms of the total viral load N h {N}_{h} at within-host scale. From equation (2.26), we see that R 0 = 1 {R}_{0}=1 implies N h = μ ( μ + π + γ 1 ) ( μ + γ 2 ) β π Λ μ d ( μ + π + γ 1 ) {{\bf{N}}}_{{\bf{h}}}=\frac{\mu \left(\mu +\pi +{\gamma }_{1})\left(\mu +{\gamma }_{2})}{\beta \pi \Lambda -\mu d\left(\mu +\pi +{\gamma }_{1})} . Therefore, we infer from this that, there is a critical value of the viral load at within-host scale depending on which the stability of the reduced multi-scale model (2.18)–(2.20) changes.

2.5
Sensitivity and elasticity

The basic reproduction number denoted by R 0 {R}_{0} is one of the most important quantities in any infectious disease models. The expression for R 0 {R}_{0} for the reduced multi-scale model (2.18)–(2.20) is given by R 0 = β N h Λ π μ ( μ + π + γ 1 ) ( μ + γ 2 + d N h ) . {R}_{0}=\frac{\beta {N}_{h}\Lambda \pi }{\mu \left(\mu +\pi +{\gamma }_{1})\left(\mu +{\gamma }_{2}+d{N}_{h})}.

To determine the best control measures, knowledge of the relative importance of the different factors responsible for transmission is useful. Initially, disease transmission is related to R 0 {R}_{0} and sensitivity predicts which parameters have a high impact on R 0 {R}_{0} . The sensitivity index of R 0 {R}_{0} with respect to a parameter μ \mu is R 0 μ \frac{\partial {R}_{0}}{\partial \mu } : another measure is the elasticity index (normalized sensitivity index) that measures the relative change of R 0 {R}_{0} with respect to μ \mu , denoted by ϕ μ R 0 {\phi }_{\mu }^{{R}_{0}} , and defined as ϕ μ R 0 = R 0 μ μ R 0 . {\phi }_{\mu }^{{R}_{0}}=\frac{\partial {R}_{0}}{\partial \mu }\frac{\mu }{{R}_{0}}.

The sign of the elasticity index tells whether R 0 {R}_{0} increases (positive sign) or decreases (negative sign) with the parameter; however, the magnitude determines the relative importance of the parameter [5,42]. These indices can guide control by indicating the most important parameters to target, although feasibility and cost play a role in practical control strategy. If R 0 {R}_{0} is known explicitly, then the elasticity index for each parameter can be computed explicitly and evaluated for a given set of parameters.

The elasticity index of R 0 {R}_{0} with the model parameters is given by ϕ β R 0 = R 0 β β R 0 = 1 , {\phi }_{\beta }^{{R}_{0}}=\frac{\partial {R}_{0}}{\partial \beta }\frac{\beta }{{R}_{0}}=1, ϕ Λ R 0 = R 0 Λ Λ R 0 = 1 , {\phi }_{\Lambda }^{{R}_{0}}=\frac{\partial {R}_{0}}{\partial \Lambda }\frac{\Lambda }{{R}_{0}}=1, ϕ π R 0 = R 0 π π R 0 = 1 , {\phi }_{\pi }^{{R}_{0}}=\frac{\partial {R}_{0}}{\partial \pi }\frac{\pi }{{R}_{0}}=1, ϕ μ R 0 = R 0 μ μ R 0 = β N h Λ π ( 3 μ 2 + 2 μ ( π + γ 1 + γ 2 + d N h ) + ( γ 2 + d ) ( π + γ 1 ) ) ( μ 3 + μ 2 ( π + γ 1 + γ 2 + d N h ) + μ ( γ 2 + d ) ( π + γ 1 ) ) μ R 0 , {\phi }_{\mu }^{{R}_{0}}=\frac{\partial {R}_{0}}{\partial \mu }\frac{\mu }{{R}_{0}}=\frac{-\beta {N}_{h}\Lambda \pi (3{\mu }^{2}+2\mu \left(\pi +{\gamma }_{1}+{\gamma }_{2}+d{N}_{h})+\left({\gamma }_{2}+d)\left(\pi +{\gamma }_{1}))}{({\mu }^{3}+{\mu }^{2}\left(\pi +{\gamma }_{1}+{\gamma }_{2}+d{N}_{h})+\mu \left({\gamma }_{2}+d)\left(\pi +{\gamma }_{1}))}\frac{\mu }{{R}_{0}}, ϕ γ 1 R 0 = R 0 γ 1 γ 1 R 0 = γ 1 ( μ + π + γ 1 ) , {\phi }_{{\gamma }_{1}}^{{R}_{0}}=\frac{\partial {R}_{0}}{\partial {\gamma }_{1}}\frac{{\gamma }_{1}}{{R}_{0}}=-\frac{{\gamma }_{1}}{\left(\mu +\pi +{\gamma }_{1})}, ϕ γ 2 R 0 = R 0 γ 2 γ 2 R 0 = γ 2 ( μ + γ 1 + d N h ) , {\phi }_{{\gamma }_{2}}^{{R}_{0}}=\frac{\partial {R}_{0}}{\partial {\gamma }_{2}}\frac{{\gamma }_{2}}{{R}_{0}}=-\frac{{\gamma }_{2}}{\left(\mu +{\gamma }_{1}+d{N}_{h})}, ϕ N h R 0 = R 0 N h N h R 0 = μ + γ 2 ( μ + γ 2 + d N h ) , {\phi }_{{N}_{h}}^{{R}_{0}}=\frac{\partial {R}_{0}}{\partial {N}_{h}}\frac{{N}_{h}}{{R}_{0}}=-\frac{\mu +{\gamma }_{2}}{\left(\mu +{\gamma }_{2}+d{N}_{h})}, ϕ d R 0 = R 0 d d R 0 = d N h ( μ + γ 2 + d N h ) . {\phi }_{d}^{{R}_{0}}=\frac{\partial {R}_{0}}{\partial d}\frac{{\rm{d}}}{{R}_{0}}=-\frac{{\rm{d}}{N}_{h}}{\left(\mu +{\gamma }_{2}+d{N}_{h})}.

The elasticity indices calculated using the parameter values from Table 3 are given in Table 2. The elastic index of parameters β , π , Λ \beta ,\pi ,\Lambda , and N h {N}_{h} are positive, and the remaining are negative. This implies that the increase in the values of these parameters increases R 0 {R}_{0} , whereas increase in the values of parameters μ , γ 1 \mu ,{\gamma }_{1} , and γ 2 {\gamma }_{2} decreases R 0 {R}_{0} . For parameter β \beta , ϕ β R 0 = 1 {\phi }_{\beta }^{{R}_{0}}=1 implies an increase (decrease) of β \beta by y % y \% increases (decreases) R 0 {R}_{0} by the same percentage. From Table 2, we see that the basic reproduction number is most sensitive to the parameters β , π \beta ,\pi , and Λ \Lambda . The implication of this is that an increase in the transmission rate increases the spread of the disease in the community.

Table 2

Elasticity indices of R 0 {R}_{0}

ParametersElastic indexValue
β \beta ϕ β R 0 {\phi }_{\beta }^{{R}_{0}} 1
π \pi ϕ π R 0 {\phi }_{\pi }^{{R}_{0}} 1
Λ \Lambda ϕ Λ R 0 {\phi }_{\Lambda }^{{R}_{0}} 1
μ \mu ϕ μ R 0 {\phi }_{\mu }^{{R}_{0}} 0.2785 &#x2012;0.2785
γ 1 {\gamma }_{1} ϕ γ 1 R 0 {\phi }_{{\gamma }_{1}}^{{R}_{0}} 0.3196 &#x2012;0.3196
γ 2 {\gamma }_{2} ϕ γ 2 R 0 {\phi }_{{\gamma }_{2}}^{{R}_{0}} 0.00082 &#x2012;0.00082
N h {N}_{h} ϕ N h R 0 {\phi }_{{N}_{h}}^{{R}_{0}} 0.0018
d d ϕ d R 0 {\phi }_{d}^{{R}_{0}} 0.99 -0.99
2.6
Numerical illustrations
2.6.1
Numerical illustrations of the stability of equilibrium points

Now, we numerically illustrate the stability of the equilibrium points admitted by Systems (2.18)–(2.20). The simulation is done using MatLab software and ode solver ode45 is used to solve the system of equations. The parameter values of the within-host sub-model used in simulation are taken from [10]. These within-host parameter values are used in calculating the area under the viral load curve N h {N}_{h} . The parameter values of the reduced multi-scale model (2.18)–(2.20) are taken from [34,39]. All the parameter values are listed in Table 3. The initial values of the variables are given in Table 4. These values are used in illustrating the stability of the equilibrium points admitted by Systems (2.18)–(2.20). We also illustrate the influence of key within-host scale sub-model parameters on the between-host scale sub-model variables.

Table 3

Parameter values

SymbolsValuesSource
ω \omega 2[10]
k k 0.05[10]
μ c {\mu }_{c} 0.1 0.1 [10]
μ v {\mu }_{v} 0.1[10]
α \alpha 0.24 0.24 [28]
x x 0.795[10]
y y 0.56[10]
Λ \Lambda μ N ( 0 ) = 71.3 \mu N\left(0)=71.3 [39]
β \beta 0.0115[39]
μ \mu 0.062[34]
π \pi 0.09[39]
d d 0.0018[39]
γ 1 , γ 2 {\gamma }_{1},{\gamma }_{2} 0.05, 0.0714[39]
Table 4

Initial values of the variables

VariableInitial valuesSource
U ( s ) U\left(s) 3.2 × 1 0 5 3.2\times 1{0}^{5} [10]
U * ( s ) {U}^{* }\left(s) 0[10]
V ( s ) V\left(s) 5.2[10]
S ( t ) S\left(t) 1,000Assumed
E ( t ) E\left(t) 100Assumed
I ( t ) I\left(t) 50Assumed

Taking d 1 = 0 {d}_{1}=0 and d 2 = 30 {d}_{2}=30 and the other parameter values from Table 3, the area under the viral load curve N h {N}_{h} is found to be 3.3759 × 1 0 4 3.3759\times 1{0}^{4} . Here, in our study, we have taken d 2 d 1 = 30 {d}_{2}-{d}_{1}=30 days as the duration of host infectivity. The value of basic reproduction number R 0 {{\boldsymbol{R}}}_{{\bf{0}}} with β = 0.00115 \beta =0.00115 and μ = 0.42 \mu =0.42 , and other parameters from Table 3 are calculated to be R 0 = 0.84 {{\boldsymbol{R}}}_{{\bf{0}}}=0.84 . Since R 0 < 1 {R}_{0}\lt 1 , by Theorem 2.3, the infection-free equilibrium point, E 0 = ( 169.76 , 0 , 0 ) {{\boldsymbol{E}}}_{{\bf{0}}}=\left(169.76,0,0) is globally asymptotically stable for Systems (2.18)–(2.20). The plots in Figures 1 and 2 for different initial conditions depict the local and global asymptotic stability of the infection-free equilibrium E 0 {E}_{0} of Systems (2.18)–(2.20).

Figure 1

Local asymptotic stability of E 0 {E}_{0} of Systems (2.18)–(2.20).

Figure 2

Global asymptotic stability of E 0 {E}_{0} of Systems (2.18)–(2.20).

We know that the infected equilibrium E 1 {E}_{1} exists only if R 0 > 1 {R}_{0}\gt 1 and it is also locally asymptotically stable whenever R 0 > 1 {R}_{0}\gt 1 . For the parameter values in Table 3, the value of R 0 {R}_{0} was calculated to be 135.7936 and E 1 {E}_{1} to be ( 8.4687 , 316.8 , and 165.03 ) \left(8.4687,316.8,\hspace{0.33em}{\rm{and}}\hspace{0.33em}165.03) . Figure 3 demonstrates that E 1 {E}_{1} is locally asymptotically stable whenever R 0 > 1 {R}_{0}\gt 1 . From Section 2.4, we know that the equilibrium point exchanges their stabilities depending on the value of R 0 {R}_{0} . In Figure 4, we show the occurrence of the trans-critical bifurcation at R 0 = 1 {R}_{0}=1 .

Figure 3

Local asymptotic stability of E 1 {E}_{1} of Systems (2.18)–(2.20) starting from the initial state ( S 0 , E 0 , I 0 ) = ( 1,000 , 100 , 50 ) . \left({S}_{0},{E}_{0},{I}_{0})=\left(\hspace{0.1em}\text{1,000}\hspace{0.1em},\hspace{0.33em}100,50).

Figure 4

Trans-critical bifurcation exhibited by Systems (2.18)–(2.20) at R 0 = 1 . {R}_{0}=1. The change in the stability of the equilibria with variation in R 0 {R}_{0} can be observed.

2.6.2
Heat plots

Here, we vary two parameters of the model (2.18)–(2.20) at a time in a certain interval and plot the value of R 0 {R}_{0} as heat plots. Heat plot has two different colors: one corresponding to the region with R 0 < 1 {R}_{0}\lt 1 and the other corresponding to R 0 > 1 {R}_{0}\gt 1 . This plot helps to find the combination of parameter values for which R 0 < 1 {R}_{0}\lt 1 and R 0 > 1 {R}_{0}\gt 1 . The blue color region in these plots corresponds to the region where R 0 < 1 {R}_{0}\lt 1 , and therefore, from Theorem 2.3, the infection-free equilibrium is globally stable in this region. The other region with green color corresponds to the region where R 0 > 1 {R}_{0}\gt 1 , and in this region, the infection-free equilibrium is unstable and there exists a unique infected equilibrium point whose stability is determined using Theorem 2.4. The stability of infected equilibria is determined using Theorem 2.4.

Parameters μ and d ̲ \underline{{\bf{Parameters}}\hspace{0.33em}\mu \hspace{0.33em}{\bf{and}}\hspace{0.33em}d}

Heat plot varying μ \mu in the interval ( 0.5 , 0.94 ) \left(0.5,0.94) and d d in the interval ( 0.001 , 0.44 ) \left(0.001,0.44) is given in Figure 5. When the values of the parameters μ \mu and d d fall in the blue colored region, the infection-free equilibrium point E 0 {E}_{0} of Systems (2.18)–(2.20) is globally asymptotically stable, and in the green colored region, it is unstable.

Figure 5

Heat plots for parameters μ \mu and d d .

Parameters π and d ̲ \underline{{\bf{Parameters}}\hspace{0.33em}\pi \hspace{0.33em}{\bf{and}}\hspace{0.33em}d}

Heat plot varying π \pi in the interval ( 0.0005 , 0.005 ) \left(0.0005,0.005) and d d in the interval ( 0.05 , 0.5 ) \left(0.05,0.5) is given in Figure 6. The infection-free equilibrium point E 0 {E}_{0} of Systems (2.18)–(2.20) is globally asymptotically stable, in the blue colored region, and unstable in the green colored region.

Figure 6

Heat plots for parameters π \pi and d d .

Parameters μ and π ̲ \underline{{\bf{Parameters}}\hspace{0.33em}\mu \hspace{0.33em}{\bf{and}}\hspace{0.33em}\pi }

Heat plot varying π \pi in the interval ( 0.004 , 0.049 ) \left(0.004,0.049) and μ \mu in the interval ( 1.05 , 1.5 ) \left(1.05,1.5) is given in Figure 7 and similarly varying β \beta in the interval ( 0.0005 , 0.005 ) \left(0.0005,0.005) and d d in the interval ( 0.05 , 0.5 ) \left(0.05,0.5) is given in Figure 8.

Figure 7

Heat plots for parameters μ \mu and π \pi .

Figure 8

Heat plots for parameters β \beta and d d .

2.6.3
Influence of within-host sub-model parameters on the between-host sub-model

In this section, we study the influence of the within-host sub-model parameters on the between-host sub-model variables. The reduced multi-scale model (2.18)–(2.20) is categorized as an NMSM according to the categorization of multi-scale model infectious disease systems [15]. Therefore, the multi-scale model (2.18)–(2.20) is unidirectionally coupled. In this only the within-host scale sub-model influences the between-host scale sub-model without any reciprocal feedback. Here, we illustrate the influence of the key within-host scale sub-model parameters such as α , y \alpha ,y , and x x on the between-host scale sub-model variable I I . At the within-host scale sub-model, α , y \alpha ,y , and x x describe the production of virus by infected cells, the clearance of the infected cells by the immune system, and the clearance rate of free virus particles by the immune system. The parameter values for the simulation are taken from Table 3.

In Figure 9, the effect of variation of burst rate of virus on infected population is plotted. The infected population I ( t ) I\left(t) is plotted for three different values of burst rate α = 0.24 \alpha =0.24 , α = 0.5 \alpha =0.5 , and α = 0.7 \alpha =0.7 . The values of N h {N}_{h} will change based on the values of α \alpha . This change in the value of N h {N}_{h} will also affect the between-host dynamics. The values of N h {N}_{h} for α = 0.24 \alpha =0.24 , α = 0.5 \alpha =0.5 , and α = 0.7 \alpha =0.7 were calculated to be 3.3759 × 1 0 4 3.3759\times 1{0}^{4} , 3.6921 × 1 0 4 3.6921\times 1{0}^{4} , and 3.8127 × 1 0 4 3.8127\times 1{0}^{4} , respectively. Figure 9 shows that the between-host scale variable I ( t ) I\left(t) is influenced by the within-host scale parameter α \alpha . We see from Figure 9 that as the infected cell burst size increases, transmission of the disease in the community also increases. Therefore, antiviral drugs such as remdesivir, arbidol, and hydroxychloroquine (HCQ) that reduce the average infected cell viral production rate at within-host scale will possibly reduce the transmission of COVID-19 disease at between-host scale.

Figure 9

Effect of variation of burst rate of virus on infected population.

In Figure 10, the effect of variation of rate of clearance of infected cells by the immune system on infected population is plotted. The infected population I ( t ) I\left(t) is plotted for three different values x = 0.5 x=0.5 , x = 0.795 x=0.795 , and x = 0.85 x=0.85 . The values of N h {N}_{h} were calculated to be 3.5149 × 1 0 4 3.5149\times 1{0}^{4} , 3.3759 × 1 0 4 3.3759\times 1{0}^{4} , and 2.8767 × 1 0 4 2.8767\times 1{0}^{4} , respectively. These numerical illustrations show that the between-host scale variable I ( t ) I\left(t) is influenced by the within-host scale parameter x x . We see from Figure 10 that as rate of clearance of infected cells by the immune system increases, the infection at population level decreases. Therefore, drugs that kill infected cells could have community-level benefits of reducing COVID-19 transmission.

Figure 10

Effect of variation of rate of clearance of infected cells by the immune system on infected population.

In Figure 11, the effect of variation of rate of clearance of virus particles by the immune system on infected population is plotted. The infected population I ( t ) I\left(t) is plotted for three different values y = 0.56 y=0.56 , y = 0.7 y=0.7 , and y = 0.8 y=0.8 . The values of N h {N}_{h} for y = 0.56 y=0.56 , y = 0.7 y=0.7 , and y = 0.8 y=0.8 were calculated to be 3.3612 × 1 0 4 3.3612\times 1{0}^{4} , 3.211 × 1 0 4 3.211\times 1{0}^{4} , and 3.1227 × 1 0 4 3.1227\times 1{0}^{4} , respectively. These numerical illustrations show that the between-host scale variable I ( t ) I\left(t) is influenced by the within-host scale parameter y y . We see from Figure 11 that as rate of clearance of virus by the immune system increases, the infection in the community decreases. Therefore, in addition to the benefits at individual level, treatments that increase the clearance rate of free virus particles in an infected individual could also have potential benefits in reducing the transmission at between-host level.

Figure 11

Effect of variation of rate of clearance of virus by the immune system on infected population.

3
Comparative effectiveness of health interventions

In this section, in similar lines to the study done in [16,36], we extend the work on the multi-scale model discussed in Section 2 by including health care interventions. In the context of infectious diseases, disease dynamics can cause a large difference between the performance of a health intervention at the individual level (within-host scale), which is easy to determine, and its performance at the population level (between-host scale), which is difficult to determine [16]. As a result, in situations where the effectiveness of a health intervention cannot be determined, health interventions with proven effectiveness may be recommended over those with potentially higher comparable effectiveness [16]. We use three health care interventions that are as follows:

1. Antiviral drugs:

  • (a)

    Drugs such as remdesivir inhibit RNA-dependent RNA polymerase, and drugs lopinavir and ritonavir inhibit the viral protease, thereby reducing viral replication [41]. Considering that these antiviral drugs are administered, the burst rate of the within-host scale sub-model α \alpha now gets modified to α ( 1 ε ) \alpha \left(1-\varepsilon ) , where ε \varepsilon is the efficacy of antiviral drugs and 0 < ε < 1 . 0\lt \varepsilon \lt 1.

  • (b)

    HCQ acts by preventing the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus from binding to cell membranes and also chloroquine/HCQ could inhibit viral entry by acting as inhibitors of the biosynthesis of sialic acids, critical actors of virus–cell ligand recognition [38]. The administration of this drug decreases the infection rate k k of susceptible cells. This parameter gets modified to become k ( 1 γ ) k\left(1-\gamma ) , where γ \gamma is the efficacy of these drugs and 0 < γ < 1 0\lt \gamma \lt 1 .

2. Immunomodulators:

Interferons are broad-spectrum antivirals, exhibiting both direct inhibitory effect on viral replication and supporting an immune response to clear virus infection [43]. Due to the administration of immunomodulators such as INF, immunity power of an individual increases as a result of which the clearance rate of infected cells and virus particles by immune response increases. Therefore, the parameters x x and y y now get modified to x ( 1 + δ ) x\left(1+\delta ) and y ( 1 + δ ) y\left(1+\delta ) , where δ \delta is the efficacy of immunomodulators and 0 < δ < 1 0\lt \delta \lt 1 .

3. Generalized social distancing:

This intervention involves introducing measures such as restriction of mass gatherings, wearing of mask, and temporarily closing schools. Assuming that generalized social distancing is introduced to control COVID-19 epidemic, then the rate of contact with community β \beta obtains modified to β ( 1 ρ ) \beta \left(1-\rho ) , where ρ \rho is the efficacy of generalized social distancing and 0 < ρ < 1 0\lt \rho \lt 1 .

Considering all the modifications in the parameters, the multi-scale model incorporating the effects of all the aforementioned health interventions becomes (3.1) d S d t = Λ β ( 1 ρ ) N m S ( t ) I ( t ) μ S ( t ) , \frac{{\rm{d}}S}{{\rm{d}}t}=\Lambda -\beta \left(1-\rho ){N}_{m}S\left(t)I\left(t)-\mu S\left(t), (3.2) d E d t = β N m S ( t ) I ( t ) ( μ + π + γ 1 ) E ( t ) , \frac{{\rm{d}}E}{{\rm{d}}t}=\beta {N}_{m}S\left(t)I\left(t)-\left(\mu +\pi +{\gamma }_{1})E\left(t), (3.3) d I d t = π E ( t ) ( μ + γ 2 ) I ( t ) d N m I ( t ) , \frac{{\rm{d}}I}{{\rm{d}}t}=\pi E\left(t)-\left(\mu +{\gamma }_{2})I\left(t)-d{N}_{m}I\left(t), where N m {N}_{m} is modified N h {N}_{h} given by (3.4) N m = α ( 1 ε ) d 1 d 2 U * d s y ( 1 + δ ) + μ v . {N}_{m}=\frac{\alpha \left(1-\varepsilon ){\int }_{{d}_{1}}^{{d}_{2}}{U}^{* }{\rm{d}}s}{y\left(1+\delta )+{\mu }_{v}}.

The effective reproduction number after incorporating the health interventions is given by R E = β ( 1 ρ ) N m Λ π μ ( μ + π + γ 1 ) ( μ + γ 2 + d N m ) . {R}_{E}=\frac{\beta \left(1-\rho ){N}_{m}\Lambda \pi }{\mu \left(\mu +\pi +{\gamma }_{1})\left(\mu +{\gamma }_{2}+d{N}_{m})}.

Here, the comparative effectiveness of the aforementioned three health interventions are evaluated using R E {R}_{E} as indicators of intervention effectiveness. In order to evaluate these, we calculate the percentage reduction of 0 {{\mathcal{ {\mathcal R} }}}_{0} for single and multiple combination of the interventions at different efficacy levels such as (a) low efficacy of 0.3, (b) medium efficacy of 0.6, and (c) high efficacy of 0.9. The different efficacy levels of the health interventions are chosen from [36].

Percentage reduction of 0 {{\mathcal{ {\mathcal R} }}}_{0} is given by 0 E j 0 × 100 , \left[\frac{{{\mathcal{ {\mathcal R} }}}_{0}-{{\mathcal{ {\mathcal R} }}}_{{E}_{j}}}{{{\mathcal{ {\mathcal R} }}}_{0}}\right]\times 100, where R E j {R}_{Ej} means the effective reproductive number when intervention/combination of interventions with efficacy/efficacies j j .

We now consider eight different combinations of these three health interventions corresponding to efficacy values 0.3, 0.6, and 0.9 obtained using the effective reproductive number R E {R}_{E} as the indicator of intervention effectiveness. Then, for each efficacy level, we rank the percentage reductions on 0 {{\mathcal{ {\mathcal R} }}}_{0} in ascending order from 1 to 8 corresponding to the different combinations of three health interventions considered in this study. The comparative effectiveness is calculated and measured on a scale from 1 to 8, with 1 denoting the lowest comparative effectiveness and 8 denoting the highest comparative effectiveness. In Table 5, the abbreviations (a) CEL stands for “comparative effectiveness at low efficacy,” which is 0.3; (b) CEM stands for “comparative effectiveness at medium efficacy,” which is 0.6; and (c) CEH stands for “comparative effectiveness at high efficacy” which is 0.9.

Table 5

Comparative effectiveness for 0 {{\mathcal{ {\mathcal R} }}}_{0}

No.Indicator% AgeCEL% AgeCEM% AgeCEH
1 0 {{\mathcal{ {\mathcal R} }}}_{0} 010101
2 E ρ {{\mathcal{ {\mathcal R} }}}_{{E}_{\rho }} 305605905
3 E δ {{\mathcal{ {\mathcal R} }}}_{{E}_{\delta }} 0.10630.2420.454
4 E ε {{\mathcal{ {\mathcal R} }}}_{{E}_{\varepsilon }} 0.07520.2630.383
5 E ρ δ {{\mathcal{ {\mathcal R} }}}_{{E}_{\rho \delta }} 30.07760.12790.457
6 E ρ ε {{\mathcal{ {\mathcal R} }}}_{{E}_{\rho \varepsilon }} 30.05660.1690.236
7 E ε δ {{\mathcal{ {\mathcal R} }}}_{{E}_{\varepsilon \delta }} 0.2240.3540.672
8 E ρ δ ε {{\mathcal{ {\mathcal R} }}}_{{E}_{\rho \delta \varepsilon }} 30.16860.34890.58

From Table 5, we deduce the following results regarding comparative effectiveness of three different interventions considered:

  • (a)

    When a single intervention strategy is implemented, intervention involving introducing measures such as restriction of mass gatherings, wearing of mask, and temporarily closing schools show a significant decrease in R 0 {R}_{0} compared to the implementation of antiviral drugs and immunomodulators at all efficacy levels.

  • (b)

    When considering two interventions, we observe that the generalized social distancing along with immunomodulators that boost the immune response would be highly effective in limiting the spread of infection in the community.

  • (c)

    A combined strategy involving treatment with antiviral drugs, immunomodulators, and generalized social distancing seems to perform the best among all the combinations considered at all efficacy levels.

From this section, we conclude that a combined strategy is the best strategy to contain the spread of infection. However, the implementation of a combined strategy may not always be cost-effective and feasible. In a single intervention strategy, generalized social distancing is shown to lower the value of R 0 {R}_{0} better than the individual use of antiviral drugs and immunomodulators. Therefore, in a situation where resources are limited and costly, interventions such as restricting mass gatherings, wearing masks, and temporarily closing schools would be highly effective in containing infection and also incur less cost.

4
Discussions and conclusions

COVID-19 is a contagious respiratory and vascular disease caused by SARS-CoV-2. The emergence of the disease has posed a major challenge to health authorities and governments around the world. The COVID -19 has spread globally and is one of the largest pandemics the world has ever seen. Mathematical models have proved to provide useful information about the dynamics of the infectious diseases in the past. To understand the dynamics of the COVID-19 disease, several models have been developed and studied [6,9,12,27,35,39,40,44,47,48]. Although these models have provided useful information about the disease transmission, disease modelers see the need to integrate or link the models at different scales (within-host and between-host) to obtain a better understanding of the dynamics of infectious disease spread.

In this study, we develop an NMSM for COVID-19 disease that integrates the within-host scale and the between-host scale sub-models. The transmission rate and COVID-19-induced death rate at between-host scale are assumed to be a linear function of viral load. Because of the difficulties of working at two different time scales, we approximate individual-level host infectiousness by some surrogate measurable quantity called area under viral load and reduce the multi-scale model at two different times scales to a model with area under the viral load curve acting as a proxy of individual level host infectiousness.

Initially, the well-posedness of the reduced multi-scale model is discussed followed by the stability analysis of the equilibrium points admitted by the reduced multi-scale model. The infection-free equilibrium point of the model is found to remain globally asymptotically stable whenever the value of basic reproduction number is less than unity. As the value of basic reproduction number crossed unity, a unique infected equilibrium point exists and remains asymptotically stable if A 1 B 1 > C 1 {A}_{1}{B}_{1}\gt {C}_{1} (Theorem 2.4). The model is shown to undergo a forward (trans-critical) bifurcation at R 0 = 1 {R}_{0}=1 . To predict the sensitivity of the model parameters on R 0 {R}_{0} , elastic index that measures the relative change of R 0 {R}_{0} with respect to parameters is calculated for each parameters in the definition of R 0 {R}_{0} . The parameters β \beta , π \pi , and Λ \Lambda were found to be most sensitive toward R 0 {R}_{0} . The theoretical results are supported with numerical illustrations. To separate out the region of stability and instability of the equilibrium points, two-parameter heat plot is done by varying the parameter values in certain range. The influence of the key within-host scale sub-model parameters such as α , y \alpha ,y , and x x on between-host scale are also numerically illustrated. It is found that the spread of infection in a community is influenced by the production of virus particles by an infected cells ( α \alpha ), clearance rate of infected cell ( x ) \left(x) , and clearance rate of virus particles by immune system ( y ) (y) .

We also use the reduced multi-scale model developed to study the comparative effectiveness of the three health interventions (antiviral drugs, immunomodulators, and generalized social distancing) for COVID-19 viral infection using R E {R}_{E} as the indicator of intervention effectiveness. The result suggested that a combined strategy involving treatment with antiviral drugs, immunomodulators, and generalized social distancing would be the best strategy to limit the spread of infection in the community. However, implementing a combined strategy may not be always cost-effective or feasible. In a single intervention strategy, general social distancing has been shown to lower the value of R 0 {R}_{0} better than the individual use of antiviral drugs and immunomodulators. Therefore, in a situation where resources are limited and costly, interventions such as restricting mass gatherings, wearing masks, and temporarily closing schools would be highly effective in containing infection and also more cost-effective.

The study performed at multi-scale level in this study highlights the dependence of between-host processes on within-host processes. With the increasing recognition of the importance of multi-scale modeling in disease dynamics, we believe that our study contributes to the growing body of knowledge on multi-scale modeling of COVID-19 disease. Two categories of people benefit from the multi-scale study: disease modelers and public health officials. Disease modelers benefit from the fact that this study provides a different approach to modeling acute viral infections. For public health planners, this study provides a model-based approach to evaluating the effectiveness of public health interventions. We also believe that the results presented in this study will help physicians, doctors, and researchers in making informed decisions about COVID-19 disease prevention and treatment interventions.

Language: English
Submitted on: Dec 21, 2023
Accepted on: May 6, 2024
Published on: Jun 21, 2024
Published by: Sciendo
In partnership with: Paradigm Publishing Services

© 2024 Bishal Chhetri, Krishna Kiran Vamsi Dasu, published by Sciendo
This work is licensed under the Creative Commons Attribution 4.0 License.